Retatrutide vs Tirzepatide vs Semaglutide: Complete 2026 Comparison

The obesity medication landscape in 2026 offers three classes of injectable weight loss drugs based on incretin receptor technology: semaglutide (a single GLP-1 agonist), tirzepatide (a dual GLP-1/GIP agonist), and retatrutide (a triple GLP-1/GIP/glucagon agonist). Each represents a generational advance in efficacy. Understanding their differences — in mechanism, clinical results, side effects, cost, and availability — is essential for anyone considering medical weight loss treatment.

Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. Always consult a qualified healthcare provider before making decisions about weight loss medications.

The Master Comparison Table

This table summarizes the key differences across all three medications based on published clinical trial data and current market information.

Feature	Semaglutide	Tirzepatide	Retatrutide
Brand Names	Wegovy (obesity), Ozempic (diabetes)	Zepbound (obesity), Mounjaro (diabetes)	Not yet branded (investigational)
Manufacturer	Novo Nordisk	Eli Lilly	Eli Lilly
Mechanism	GLP-1 agonist (1 receptor)	GLP-1 + GIP agonist (2 receptors)	GLP-1 + GIP + Glucagon agonist (3 receptors)
Avg Weight Loss	14.9% (68 weeks)	22.5% (72 weeks)	24.2% (48 weeks)
Max Dose	2.4 mg/week	15 mg/week	12 mg/week (Phase 2)
Route	Weekly subcutaneous injection	Weekly subcutaneous injection	Weekly subcutaneous injection
FDA Status	Approved (2021)	Approved (2023)	Phase 3 trials (est. 2026-2027)
List Price/Month	~$1,349/month	~$1,059/month	TBD (projected $1,000-1,500)
GI Side Effects	Nausea 44%, Diarrhea 30%, Vomiting 24%	Nausea 31%, Diarrhea 23%, Vomiting 12%	Nausea 26%, Diarrhea 22%, Vomiting 13%
Pivotal Trials	STEP program	SURMOUNT program	TRIUMPH program

Mechanism of Action: 1 vs 2 vs 3 Receptors

The fundamental difference between these three drugs is how many metabolic hormone receptors each one activates. This is not merely a marketing distinction — each additional receptor target engages distinct physiological pathways that contribute to greater weight loss.

Semaglutide: The Single Agonist Foundation

Semaglutide activates only GLP-1 receptors. This reduces appetite through hypothalamic signaling, slows gastric emptying to increase meal satiety, and improves insulin sensitivity. The GLP-1 mechanism primarily reduces caloric intake — patients eat less because they feel less hungry and feel full sooner. Semaglutide proved that targeting incretin receptors could produce clinically meaningful weight loss, but its approximately 15% average reduction left room for improvement.

Tirzepatide: The Dual Agonist Advance

Tirzepatide added GIP receptor activation to the GLP-1 foundation. GIP enhances insulin secretion, improves lipid metabolism, and may contribute to better fat tissue remodeling. The dual mechanism boosted average weight loss to 22.5% — a 50% improvement over semaglutide. GIP activation also appears to improve GI tolerability, which is why tirzepatide has lower nausea rates than semaglutide despite producing more weight loss.

Retatrutide: The Triple Agonist Breakthrough

Retatrutide added glucagon receptor activation to the GLP-1/GIP foundation. This is transformative because glucagon increases energy expenditure — it makes the body burn more calories at rest. While semaglutide and tirzepatide primarily work by reducing energy intake, retatrutide also increases energy output. This dual-sided approach to the energy balance equation explains the step-change in results. The 24.2% weight loss at 48 weeks is notable not just for the percentage but for the timeline: this was achieved in 48 weeks, while tirzepatide's 22.5% required 72 weeks. Adjusted for time, retatrutide is losing weight at roughly 50% faster rate.

Weight Loss Results: Head-to-Head Data

No head-to-head clinical trial has directly compared all three drugs. However, we can compare results across their respective pivotal trials while acknowledging that cross-trial comparisons have limitations (different patient populations, trial designs, and durations).

Metric	Semaglutide 2.4mg	Tirzepatide 15mg	Retatrutide 12mg
Trial	STEP 1	SURMOUNT-1	Phase 2 (Jastreboff 2023)
Duration	68 weeks	72 weeks	48 weeks
Avg Weight Loss	14.9%	22.5%	24.2%
Lost >20% body weight	32%	57%	~65%
Weight loss plateau?	Yes, ~60 weeks	Near plateau at 72 weeks	No plateau at 48 weeks

The fact that retatrutide achieved 24.2% weight loss in only 48 weeks — with no plateau — is perhaps its most compelling data point. Both semaglutide and tirzepatide show weight loss deceleration by 60-72 weeks. Retatrutide's weight loss curve was still accelerating when the Phase 2 trial ended, strongly suggesting that longer treatment will yield even greater reductions. Phase 3 TRIUMPH data from 68-week treatment periods will clarify the ultimate ceiling.

Side Effect Comparison

All three medications share a similar gastrointestinal side effect profile because they all activate GLP-1 receptors, which slow gastric emptying. However, the rates and severity differ meaningfully.

Semaglutide has the highest rates of nausea (44%), diarrhea (30%), and vomiting (24%) among the three drugs. This is likely because GLP-1 receptor activation alone drives strong gastric emptying effects without the moderating influence of GIP. Many patients find the nausea manageable and it typically diminishes after 4-8 weeks, but it remains the primary reason patients discontinue semaglutide.

Tirzepatide has noticeably lower GI side effect rates despite producing greater weight loss. Nausea occurs in about 31% of patients, diarrhea in 23%, and vomiting in 12%. The GIP receptor activation appears to partially buffer the GI effects of GLP-1, improving tolerability.

Retatrutide showed GI side effect rates comparable to tirzepatide in Phase 2 data: nausea around 26%, diarrhea 22%, and vomiting 13%. The glucagon component adds a unique consideration: transient increases in heart rate and hepatic enzyme elevations have been observed, requiring monitoring. These effects were generally mild and did not lead to treatment discontinuation in Phase 2, but Phase 3 data will provide a clearer safety picture.

Cost and Availability

Currently, semaglutide and tirzepatide are both commercially available. Semaglutide (Wegovy) carries a list price of approximately $1,349 per month, though manufacturer savings programs and insurance can significantly reduce this. Tirzepatide (Zepbound) lists at approximately $1,059 per month. Trimi offers both semaglutide and tirzepatide at competitive cash-pay prices through compounding partnerships.

Retatrutide pricing has not been announced, as the drug is still in Phase 3 trials. Based on Eli Lilly's pricing strategy with tirzepatide and the competitive dynamics of the obesity drug market, analysts project retatrutide could launch at $1,000-1,500 per month at list price, with potential for compounded versions after patent considerations.

When to Choose Each Medication

Choose Semaglutide If:

You want a well-established drug with years of real-world safety data
Your weight loss goal is moderate (10-15% body weight)
You have cardiovascular disease and want the SELECT trial cardio protection data
You prefer the option of an oral formulation (Rybelsus)
Cost is a primary concern and compounded semaglutide is available

Choose Tirzepatide If:

You need more aggressive weight loss (20%+ body weight)
GI side effects on semaglutide were intolerable
You have significant insulin resistance or type 2 diabetes
You want the most effective FDA-approved option available today
You tried semaglutide and plateaued

Consider Waiting for Retatrutide If:

You have very high BMI (40+) and need maximum possible weight loss
You have not responded adequately to semaglutide or tirzepatide
You are willing to participate in clinical trials
You are interested in the metabolic rate increase from the glucagon component

However, our general recommendation is not to wait. Starting treatment with semaglutide or tirzepatide now provides meaningful health benefits immediately, and patients can potentially transition to retatrutide when it becomes available. Learn how to get started with Trimi.

Frequently Asked Questions

Which is the most effective weight loss drug?

Based on clinical trial data, retatrutide has produced the highest average weight loss (24.2% at 48 weeks). However, it is not yet FDA-approved. Among approved medications, tirzepatide (22.5% at 72 weeks) is the most effective, followed by semaglutide (14.9% at 68 weeks).

Can I switch from semaglutide to tirzepatide or retatrutide?

Switching from semaglutide to tirzepatide is common and generally safe when done under medical supervision. Switching to retatrutide will only be possible once it receives FDA approval. Trimi's medical team can guide transitions between medications — read our switching guide.

Which drug has the fewest side effects?

Tirzepatide and retatrutide have shown lower rates of nausea and vomiting compared to semaglutide. Retatrutide had the lowest nausea rate in Phase 2 (26%), though Phase 3 data will provide more definitive comparisons.

Will Trimi offer retatrutide?

Trimi plans to offer retatrutide when it becomes commercially available. Currently, Trimi offers both semaglutide and tirzepatide as treatment options.

Should I wait for retatrutide or start treatment now?

We recommend starting treatment now with an available medication rather than waiting. Obesity is a progressive disease, and delaying treatment allows weight-related health complications to worsen. Patients who start with semaglutide or tirzepatide can transition to retatrutide later if desired.

Do these drugs require a prescription?

Yes. All three medications require a prescription from a licensed healthcare provider. Trimi's telehealth platform connects you with licensed providers who can evaluate your eligibility and prescribe the appropriate medication.